First-Trimester Levels of Pregnancy-Associated Plasma Protein A2 (PAPP-A2) in the Maternal Circulation Are Elevated in Pregnancies That Subsequently Develop Preeclampsia

Cross JC. The genetics of pre-eclampsia: a feto-placental or maternal problem? Clin Genet. 2003;64(2):96–103.

Kinzler WL, Vintzileos AM. Fetal growth restriction: a modern approach. Curr Opin Obstet Gynecol. 2008;20(2):125–131.

Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.

von Dadelszen P, Magee L. What matters in preeclampsia are the associated adverse outcomes: the view from Canada. Curr Opin Obstet Gynecol. 2008;20(2):110–115.

Godfrey KM. The role of the placenta in fetal programming—a review. Placenta. 2002;23(suppl A):S20–S27.

Nayak NR, Giudice LC. Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta. 2003; 24(4):281–296.

Sferruzzi-Perri AN, Owens JA, Pringle KG, Roberts CT. The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth. J Physiol. 2011;589(pt 1): 7–20.

Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967–E976.

Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab. 2003;14(4):176–181.

Murphy LJ. Insulin-like growth factor-binding proteins: functional diversity or redundancy? J Mol Endocrinol. 1998;21(2): 97–107.

Giudice LC, Conover CA, Bale L, et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for para-crine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab. 2002;87: 2359–2366.

Boldt HB, Kjaer-Sorensen K, Overgaard MT, et al. The Lin12-notch repeats of pregnancy-associated plasma protein-A bind calcium and determine its proteolytic specificity. J Biol Chem. 2004; 279:38525–38531.

Boldt HB, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007;17:10–18.

Brambati B, Macintosh MC, Teisner B, et al. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol. 1993;100:324–326.

Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004; 83:37–45.

Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191:1446–1451.

Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87:1762–1767.

Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25:949–953.

Zwahlen M, Gerber S, Bersinger NA. First trimester markers for pre-eclampsia: placental vs. non-placental protein serum levels. Gynecol Obstet Invest. 2007;63:15–21.

Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007;27: 264–271.

Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010;30(4):293–308.

Farr M, Strube J, Geppert HG, Kocourek A, Mahne M, Tschesche H. Pregnancy-associated plasma protein-E (PAPP-E). Biochim Biophys Acta. 2000;1493(3):356–362.

Page NM, Butlin DJ, Lomthaisong K, Lowry PJ. The characterization of pregnancy associated plasma protein-E and the identification of an alternative splice variant. Placenta. 2001;22(8–9):681–687.

Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276(24):21849–21853.

Buimer M, Keijser R, Jebbink JM, et al. Seven placental transcripts characterize HELLP-syndrome. Placenta. 2008;29(5):444–453.

Sitras V, Paulssen RH, Gronaas H, et al. Differential placental gene expression in severe preeclampsia. Placenta. 2009;30(5):424–433.

Nishizawa H, Pryor-Koishi K, Suzuki M, et al. Increased levels of pregnancy-associated plasma protein-A2 in the serum of preeclamptic patients. Mol Hum Reprod. 2008;14(10):595–602.

Winn VD, Gormley M, Paquet AC, et al. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology. 2009;150(1):452–462.

Paiva P, Whitehead C, Saglam B, Palmer K, Tong S. Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia. J Clin Endocrinol Metab. 2011;96(11):E1807–E1815.

Varkonyi T, Nagy B, Fule T, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 2011;32 suppl:S21–S29.

Macintire K, Tuohey L, Ye L, et al. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia [published online March 14, 2013]. Reprod Fertil Dev. 2013. doi:10.1071/RD12384.

Dopierala JA, Smith GC, Charnock-Jones SD. Meta-analysis of pre-eclampsia microarray data. Reprod Sci. 2013;20(3 suppl): 262A.

von Dadelszen P, Menzies JM, Payne B, Magee LA; PIERS (Preeclampsia Integrated Estimate of RiSk) Study Group. Predicting adverse outcomes in women with severe pre-eclampsia. Semin Perinatol. 2009;33(3):152–157.

Wagner PK, Christians JK. Altered placental expression of PAPPA2 does not affect birth weight in mice. Reprod Biol Endocrinol. 2010;8:90.

Wang J, Qiu Q, Haider M, Bell M, Gruslin A, Christians JK. Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse. J Endocrinol. 2009;202(3): 337–345.

Yan X, Baxter RC, Firth SM. Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab. 2010;95(3):1412–1420.

Christians JK, Gruslin A. Altered levels of insulin-like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010;30(9):815–820.

Wagner PK, Otomo A, Christians JK. Regulation of pregnancy-associated plasma protein A2 (PAPPA2) in a human placental trophoblast cell line (BeWo). Reprod Biol Endocrinol. 2011;9:48.

Kramer A, Hoffman C, Lynch A, Winn VD. Maternal serum PAPP-A2 levels are elevated in early onset preeclampsia at time of diagnosis and in early gestation. Reprod Sci. 2012;19(3 suppl): 87A.

Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks. Prenat Diagn. 2010;30(3):216–223.

Whitehead CL, Walker SP, Ye L, et al. Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab. 2013;98(3):E429–E436.